Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-10-27
2008-12-23
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S021000
Reexamination Certificate
active
07468358
ABSTRACT:
A method and medicament for treating and preventing platelet activation or thrombosis in the presence of heparin-and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater and an average molecular weight or 2.4 kD or greater. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin.
REFERENCES:
patent: 5668118 (1997-09-01), Kennedy et al.
patent: 5707974 (1998-01-01), Kennedy
patent: 5912237 (1999-06-01), Kennedy
patent: 5990097 (1999-11-01), Kennedy
patent: 6077683 (2000-06-01), Kennedy
patent: 6489311 (2002-12-01), Kennedy et al.
patent: 6743426 (2004-06-01), Fisher et al.
patent: 2005/0261241 (2005-11-01), Cardin
patent: 2005/0282775 (2005-12-01), Kennedy
patent: WO98/04133 (1998-02-01), None
patent: WO01/19376 (2001-03-01), None
patent: WO 01/82918 (2001-11-01), None
patent: WO 2004/050673 (2004-06-01), None
patent: WO 2006/007392 (2006-01-01), None
Walenga et al., “Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy”,Hematology/Oncology Clinics of North America, 2003, pp. 259-282, vol. 17.
Messmore et al., “Benefit-Risk Assessment of Treatments for Heparin-Induced Thrombocytopenia”,Drug Safety 2003, 2003, pp. 625-641.
Fabris et al., “Pathophysiology of Heparin-Induced Thrombocytopenia”,Arch Pathol Lab Med, Nov. 2000, pp. 1657-1666, vol. 124.
Walenga et al., “Mechanisms of Venous and Arterial Thrombosis in Heparin-Induced Thrombocytopenia”,Journal of Thrombosis and Thrombolysis, 2000, pp. S13-S20.
Walenga et al., “Vascular Damage Correlates Between Heparin-Induced Thrombocytopenia and the Antiphospholipid Syndrome”,Clin Appl Thrombosis/Hemostasis, 1999, pp. S76-S84, vol. 5.
Walenga et al., “Newer Insights on the Mechanism of Heparin-Induced Thrombocytopenia”,Seminars in Thrombosis and Hemostatis, 2004, pp. 57-67, vol. 30, Supplement 1.
Walenga et al., “Relative Heparin-Induced Thrombocytopenic Potential of Low Molecular Weight Heparins and New Antithrombotic Agents”,Clin Appl Thrombosis/Hemostasis, 1996, pp. S21-S27, vol. 2.
Haas et al., “Heparin-induced Thrombocytopenia: Clinical Considerations of Alternative Anticoagulation with Various Glycosaminoglycans and Thrombin Inhibitors”,Clin Appl Thrombosis/Hemostasis, 1999, pp. 52-59, vol. 5.
Jeske et al., “Heparin-Induced Thrombocytopenic Potential of GAG and Non-GAG-Based Antithrombotic Agents”,Clin Appl Thrombosis/Hemostasis, 1999, pp. S56-S62, vol. 5.
Walenga et al., “Biochemical and Pharmacologic Rationale for the Development of a Synthetic Heparin Pentasaccharide”,Thrombosis Research, 1997, pp. 1-36, vol. 86, No. 1.
Walenga et al., “Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent”,Expert Opin. Investig. Drugs, 2002, pp. 397-407, vol. 11.
Ahmad et al., “Synthetic Pentasaccharides Do Not Cause Platelet Activation by Antiheparin-Platelet Factor 4 Antibodies”,Clin Appl Thrombosis/Hemostasis, 1999, pp. 259-266, vol. 5.
Walenga et al., “Decreased Prevalence of Heparin-Induced Thrombocytopenia with Low-Molecular-Weight Heparin and Related Drugs”,Seminars in Thrombosis and Hemostasis, 2004, pp. 69-80,, vol. 30, supplement 1.
Ahmad, S., et al., “Functional Heterogeneity of Antiheparin-Platelet Factor 4 Antibodies: Implications in the Pathogenesis of the HIT Syndrome,”Clinical and Applied Thrombosis/Hemostatis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostatis, 1999, pp. S32-S37, vol. 5(1).
Fryer A. et al., “Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung”,The Journal of Pharmacology and Experimental Therapeutics, vol. 282, No. 1, Jul. 1997 pp. 208-219.
Thourani Vinod H. et al., “Nonanticoagulant heparin inhibits NF-κB- activation and attenuates myocardial reperfusion injury”,American Journal of Physiology, vol. 278, No. 6 Part 2, Jun. 2000, pp. H2084-H2093.
Greinacher Andreas et al., “Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia”,Thrombosis and Haemostasis, vol. 74, No. 3, 1995, pp. 886-892.
Kennedy Thomas Preston
Walenga Jeanine M.
Alston & Bird LLP
Jiang Shaojia Anna
Olson Eric S
Paringenix, Inc.
LandOfFree
Method and medicament for sulfated polysaccharide treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and medicament for sulfated polysaccharide treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and medicament for sulfated polysaccharide treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4027227